It is clear that despite there being a long road ahead until digital therapeutics are fully integrated into the healthcare ecosystem, their potential to improve patient outcomes for many chronic diseases is undeniable.

More and more pharma giants, such as Novartis, are recognizing this potential.

This is highlighted given Sandoz (A division of Novartis) and Pear Therapeutic’s commercial launch of reSET® last week.

You can access the full article here via Endpoints News: